Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 657.80

+1.7%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (103)	5/20/1997 12:03:00 AM
From: Mark Fisner	of 3557

Miljenko and Richard: Thanks for the rapid response - clearly I've got to do more homework. Miljenko: I have found an article online from 1995 discussing a meeting where REGN scientists reported: 1) infusion of NT-4/5, BDNF, NT-3 or NGF into rats whose cholinergic (chol.) input to the hippocampus had been disrupted showed sprouting of new chol. fibers in the hipp. The new outgrowth formed a dense plexus and resembled normal hipp/chol. input [A. Altar]. 2) In a transplant/Parkinson's model, fetal dopaminergic neurons send out more fibers and show greater overall outgrowth when recipients receive BDNF along with the transplant [D. Yurek]. Don't these studies indicate a potential therapeutic role for these GFs in AD and Parkinson's, repectively? My contention is that, by the time a diagnosis is made, growth factor treatment will be rescuing such a small remnant of the effected cell population, sprouting won't be sufficient to be clinically significant. Mark

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next